April 26, 2017 News by Joana Fernandes, PhD Sanofi Genzyme to Present New Data on MS Treatments Lemtrada and Aubagio Sanofi Genzyme will present new results on follow-up studies of its products Lemtrada (alemtuzumab) and Aubagio (teriflunomide), both of which have been approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). The new data will be presented at the American Academy of Neurology (AAN) Annual MeetingĀ taking…
April 19, 2017 News by Patricia Inacio, PhD Sanofi Genzyme to Discuss Three Multiple Sclerosis Therapies at Boston Event Sanofi GenzymeĀ will discuss three of its multiple sclerosis therapies at theĀ American Academy of Neurology annual meetingĀ in Boston, April 22-28. The presentations will cover two approved treatments for relapsing MS ā LemtradaĀ (alemtuzumab) and AubagioĀ (teriflunomide) ā and one that has been in a Phase 1 clinical…
September 20, 2016 News by Patricia Silva, PhD #ECTRIMS2016 – Sanofi Releases Patients’ Views of Aubagio as Effective Treatment for Relapsing MS Sanofi GenzymeĀ presented positive results from itsĀ Phase 4 study into patient-reported assessments ofĀ Aubagio (teriflunomide), an approved oral treatmentĀ for relapsing forms of multiple sclerosis (RMS). Real-world patient responses were reported at the 32ndĀ Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), recentlyĀ held in London. The clinical…
June 13, 2016 News by Patricia Silva, PhD Genmab to Begin Phase 3 Trials of Ofatumumab to Treat Relapsing Multiple Sclerosis GenmabĀ announced plans to soon begin a Phase 3Ā clinical trial program assessing the subcutaneous formulation of ofatumumabĀ as a potential treatment forĀ relapsing multiple sclerosis (MS). The company, workingĀ in collaboration with its partnerĀ Novartis, will begin enrolling patients in September in trials that willĀ evaluate the efficacy and safety of ofatumumab compared…
April 18, 2016 News by Patricia Silva, PhD Sanofi Genzyme Presenting New Data on Its Approved and Investigational Multiple Sclerosis Treatments at AAN Sanofi GenzymeĀ will present new data onĀ itsĀ approved multiple sclerosis (MS) treatments āĀ LemtradaĀ (alemtuzumab) and AubagioĀ (teriflunomide) ā at the 68thĀ annual meeting of the American Academy of Neurology (AAN), taking place in Vancouver, Canada, through April 21, as well asĀ data on investigational therapies in its pipeline. In total, the meeting…
April 1, 2016 News by Malika Ammam, PhD Study Finds Aubagio Well-tolerated and Efficient in Long-term MS Treatment Researchers at the University of Texas Health Science Center at Houston, in collaboration with various institutions from north America and Europe, found that teriflunomide (Aubagio) is well-tolerated and efficient for long-term treatment of multiple sclerosis (MS). The findings, entitled āLong-term safety and efficacy of teriflunomide,ā were…
March 21, 2016 News by Patricia Silva, PhD CONy16: Sanofi Genzyme Symposium on MS Therapies Targeting T and B Cells; Exclusive Interview with Lead Researcher Sanofi Genzyme,Ā one of the companies participatingĀ in the four-dayĀ 10th World Congress on Controversies in Neurology (CONy) in Lisbon, Portugal, that concludedĀ on March 20, 2016, supported several symposiums focused on multiple sclerosis (MS) ā including one on B-cell and T-cell therapies. For over a decade, Sanofi Genzyme has workedĀ to developĀ effective therapies…
December 14, 2015 News by Patricia Silva, PhD 2 New Treatments for Relapsing-Remitting MS Now Available in New Zealand The Multiple Sclerosis Society of New Zealand (MSNZ)Ā announced thatĀ PHARMAC has agreed with its requestĀ toĀ finance two novel first-in-line therapies for relapsing-remitting forms of multiple sclerosis (MS), making them accessible to patients there. PHARMAC recently agreed to fund theĀ two treatments, teriflunomide (Aubagio), supplied by Sanofi-Aventis NZ, and dimethyl fumarate (Tecfidera),…
October 13, 2015 News by Patricia Silva, PhD Insights into Promising MS Therapies at Late Breaking News Session, ECTRIMS 2015 A session titled āLate Breaking Newsā was featured at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 7-10, 2015, in Barcelona, Spain. At this session, Prof. Xavier Montalban from the Hospital Vall d’Hebron University in Barcelona presented data on the promising Genentech/Roche…
September 17, 2015 News by Patricia Silva, PhD Review on Teriflunomide (AUBAGIO), an Oral Therapy for Relapsing Multiple Sclerosis A review recently published in the journal Clinical Therapeutics focused on teriflunomide as a treatment for patients with relapsing multiple sclerosis (MS), taking into account its reported clinical efficacy and safety. The study is entitled āTeriflunomide: A Once-Daily Oral Medication for the Treatment of…
June 26, 2015 News by Charles Moore Health Canada Non-Insured Health Benefits Program Approves AUBAGIO for Relapsing Remitting Multiple Sclerosis Genzyme Canada has announced that Health Canada has approved its 14 mg dose of AUBAGIO as an expedited exception benefit product through the federal health regulator’s Non-Insured Health Benefits (NIHB) Program for eligible First Nations people and Inuit as a first-line oral tablet therapy for relapsing remitting multiple sclerosis (RRMS).
December 2, 2014 News by Patricia Silva, PhD Aubagio for Relapsing-Remitting MS Now Funded in Alberta Genzyme, a Sanofi company with over 30 years of dedication to researching and developing novel treatments for rare and orphan diseases, has just announced the Alberta Drug Program has finally decided to include AubagioĀ® (teriflunomide) 14mg in the provincial drug formulary, indicated for the first-line…
October 27, 2014 News by Patricia Silva, PhD Positive Data from Two Key MS Trials Added To Aubagio’s U.S. Label The Food and Drug Administration (FDA) recently accepted the results from Genzyme’s TOWER and TOPIC Ā clinical trials,Ā which assessed the safety and efficacy of oral, once-daily AubagioĀ® (teriflunomide) for Multiple Sclerosis, and will add the positive data to the productās U.S. label. Genzyme is a leader in the development…
October 16, 2014 News by Patricia Silva, PhD Revenge Star Madeleine Stowe is the New Face of Multiple Sclerosis Featureflash / Shutterstock.com Television’s “Queen of Mean,” Revenge‘s Madeleine Stowe,Ā recently opened up about her early memories of her father living with multiple sclerosis (MS), a progressive neurodegenerative disease that, until today, does not have a known cure. However, thanks to the efforts of countless researchers and MS…